 Patients were randomly assigned to either CCRT alone observation arm or CCRT followed by CC consolidation arm. All patients received four cycles of weekly docetaxel 25mgm2 and nedaplatin 25mgm2DP, each of 1 days duration, combined with split-course thoracic radiotherapy of 51 Gy17 fractions and 15 Gy5 fractions administered in the first and second courses, respectively, with one-month break. In the consolidation arm, patients were further treated with two cycles of pemetrexed 500mgm2 in non-squamous lung cancer or docetaxel 60mgm2 in squamous lung cancer, each of 3 days duration, every 3 weeks. The primary end point is progression-free survival, which is the time that passes from the first day of radiotherapy to the date on which disease progresses. Progression-free survival will be calculated and compared using the Kaplan-Meier method. Toxicities will be graded according to CTCAE v. 4.0. 